221 related articles for article (PubMed ID: 18647411)
21. Differences in Cellular Composition of Peripheral Blood Stem Cell Grafts from Healthy Stem Cell Donors Mobilized with Either Granulocyte Colony-Stimulating Factor (G-CSF) Alone or G-CSF and Plerixafor.
Teipel R; Oelschlägel U; Wetzko K; Schmiedgen M; Kramer M; Rücker-Braun E; Hölig K; von Bonin M; Heidrich K; Fuchs A; Ordemann R; Kroschinsky F; Bornhäuser M; Hütter G; Schmidt H; Ehninger G; Schetelig J; Heidenreich F
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2171-2177. PubMed ID: 29935214
[TBL] [Abstract][Full Text] [Related]
22. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
Steinberg M; Silva M
Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
[TBL] [Abstract][Full Text] [Related]
23. The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen.
Menéndez P; Caballero MD; Prosper F; Del Cañizo MC; Pérez-Simón JA; Mateos MV; Nieto MJ; Corral M; Romero M; García-Conde J; Montalbán MA; San Miguel JF; Orfao A
Transfusion; 2002 Sep; 42(9):1159-72. PubMed ID: 12430673
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
Li J; Hamilton E; Vaughn L; Graiser M; Renfroe H; Lechowicz MJ; Langston A; Prichard JM; Anderson D; Gleason C; Lonial S; Flowers CR; Kaufman JL; Waller EK
Transfusion; 2011 Oct; 51(10):2175-82. PubMed ID: 21492180
[TBL] [Abstract][Full Text] [Related]
25. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma.
Cashen A; Lopez S; Gao F; Calandra G; MacFarland R; Badel K; DiPersio J
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1253-61. PubMed ID: 18940680
[TBL] [Abstract][Full Text] [Related]
26. A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study.
Fruehauf S; Veldwijk MR; Seeger T; Schubert M; Laufs S; Topaly J; Wuchter P; Dillmann F; Eckstein V; Wenz F; Goldschmidt H; Ho AD; Calandra G
Cytotherapy; 2009; 11(8):992-1001. PubMed ID: 19929463
[TBL] [Abstract][Full Text] [Related]
27. FL/GCSF/AMD3100-mobilized Hematopoietic Stem Cells Induce Mixed Chimerism With Nonmyeloablative Conditioning and Transplantation Tolerance.
Xu H; Zhu Z; Huang Y; Ildstad ST
Transplantation; 2019 Jul; 103(7):1360-1371. PubMed ID: 30747856
[TBL] [Abstract][Full Text] [Related]
28. Plerixafor+G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy.
Karponi G; Psatha N; Lederer CW; Adair JE; Zervou F; Zogas N; Kleanthous M; Tsatalas C; Anagnostopoulos A; Sadelain M; Rivière I; Stamatoyannopoulos G; Yannaki E
Blood; 2015 Jul; 126(5):616-9. PubMed ID: 26089395
[TBL] [Abstract][Full Text] [Related]
29. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist.
Broxmeyer HE; Orschell CM; Clapp DW; Hangoc G; Cooper S; Plett PA; Liles WC; Li X; Graham-Evans B; Campbell TB; Calandra G; Bridger G; Dale DC; Srour EF
J Exp Med; 2005 Apr; 201(8):1307-18. PubMed ID: 15837815
[TBL] [Abstract][Full Text] [Related]
30. Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor.
Farina L; Spina F; Guidetti A; Longoni P; Ravagnani F; Dodero A; Montefusco V; Carlo-Stella C; Corradini P
Leuk Lymphoma; 2014 Feb; 55(2):331-6. PubMed ID: 23656194
[TBL] [Abstract][Full Text] [Related]
31. Addition of plerixafor for CD34+ cell mobilization in six healthy stem cell donors ensured satisfactory grafts for transplantation.
Hauge AW; Haastrup EK; Sengeløv H; Minulescu L; Dickmeiss E; Fischer-Nielsen A
Transfusion; 2014 Apr; 54(4):1055-8. PubMed ID: 23944772
[TBL] [Abstract][Full Text] [Related]
32. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone.
Flomenberg N; Devine SM; Dipersio JF; Liesveld JL; McCarty JM; Rowley SD; Vesole DH; Badel K; Calandra G
Blood; 2005 Sep; 106(5):1867-74. PubMed ID: 15890685
[TBL] [Abstract][Full Text] [Related]
33. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation.
Lane TA; Law P; Maruyama M; Young D; Burgess J; Mullen M; Mealiffe M; Terstappen LW; Hardwick A; Moubayed M
Blood; 1995 Jan; 85(1):275-82. PubMed ID: 7528570
[TBL] [Abstract][Full Text] [Related]
34. Comparison of retroviral transduction efficiency in CD34+ cells derived from bone marrow versus G-CSF-mobilized or G-CSF plus stem cell factor-mobilized peripheral blood in nonhuman primates.
Hematti P; Tuchman S; Larochelle A; Metzger ME; Donahue RE; Tisdale JF
Stem Cells; 2004; 22(6):1062-9. PubMed ID: 15536196
[TBL] [Abstract][Full Text] [Related]
35. Collection and Processing of Mobilized Mouse Peripheral Blood at Lowered Oxygen Tension Yields Enhanced Numbers of Hematopoietic Stem Cells.
Aljoufi A; Cooper S; Broxmeyer HE
Stem Cell Rev Rep; 2020 Oct; 16(5):946-953. PubMed ID: 32748332
[TBL] [Abstract][Full Text] [Related]
36. Effect of high-dose plerixafor on CD34
Pantin J; Purev E; Tian X; Cook L; Donohue-Jerussi T; Cho E; Reger R; Hsieh M; Khuu H; Calandra G; Geller NL; Childs RW
Haematologica; 2017 Mar; 102(3):600-609. PubMed ID: 27846612
[TBL] [Abstract][Full Text] [Related]
37. Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol.
Micallef IN; Stiff PJ; DiPersio JF; Maziarz RT; McCarty JM; Bridger G; Calandra G
Biol Blood Marrow Transplant; 2009 Dec; 15(12):1578-86. PubMed ID: 19896082
[TBL] [Abstract][Full Text] [Related]
38. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.
Pusic I; Jiang SY; Landua S; Uy GL; Rettig MP; Cashen AF; Westervelt P; Vij R; Abboud CN; Stockerl-Goldstein KE; Sempek DS; Smith AL; DiPersio JF
Biol Blood Marrow Transplant; 2008 Sep; 14(9):1045-1056. PubMed ID: 18721768
[TBL] [Abstract][Full Text] [Related]
39. Mobilization of hematopoietic stem cells with highest self-renewal by G-CSF precedes clonogenic cell mobilization peak.
Winkler IG; Wiercinska E; Barbier V; Nowlan B; Bonig H; Levesque JP
Exp Hematol; 2016 Apr; 44(4):303-14.e1. PubMed ID: 26827874
[TBL] [Abstract][Full Text] [Related]
40. Collection of hematopoietic CD34 stem cells in rhesus macaques using Spectra Optia.
Haynes LD; Coonen J; Post J; Brunner K; Bloom D; Hematti P; Kaufman DB
J Clin Apher; 2017 Oct; 32(5):288-294. PubMed ID: 27578423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
